| Basics |
Medpace Holdings, Inc.
Medpace Holdings Inc is a clinical contract research organisation. It is engaged in providing scientifically-driven clinical research-based drug and medical device development services to the biotechnology, pharmaceutical and medical device industries.
|
| IPO Date: |
August 11, 2016 |
| Sector: |
Healthcare |
| Industry: |
Medical Diagnostics and Research |
| Market Cap: |
$15.44B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$2.69 | 1.63%
|
| Avg Daily Range (30 D): |
$6.80 | 1.15%
|
| Avg Daily Range (90 D): |
$6.58 | 1.27%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.28M |
| Avg Daily Volume (30 D): |
.23M |
| Avg Daily Volume (90 D): |
.24M |
| Trade Size |
| Avg Trade Size (Sh.): |
45 |
| Avg Trade Size (Sh.) (30 D): |
20 |
| Avg Trade Size (Sh.) (90 D): |
23 |
| Institutional Trades |
| Total Inst.Trades: |
3,074 |
| Avg Inst. Trade: |
$6.21M |
| Avg Inst. Trade (30 D): |
$17.57M |
| Avg Inst. Trade (90 D): |
$19.78M |
| Avg Inst. Trade Volume: |
.04M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$7.52M |
| Avg Closing Trade (30 D): |
$21.39M |
| Avg Closing Trade (90 D): |
$22.23M |
| Avg Closing Volume: |
40.92K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$14.66
|
$3.95
|
$3.16
|
|
Diluted EPS
|
$14.31
|
$3.86
|
$3.1
|
|
Revenue
|
$ 2.36B
|
$ 659.9M
|
$ 603.31M
|
|
Gross Profit
|
$ 733.62M
|
$ 196.94M
|
$ 180.01M
|
|
Net Income / Loss
|
$ 433.01M
|
$ 111.14M
|
$ 90.26M
|
|
Operating Income / Loss
|
$ 507.04M
|
$ 141.81M
|
$ 126.34M
|
|
Cost of Revenue
|
$ 1.62B
|
$ 462.96M
|
$ 423.3M
|
|
Net Cash Flow
|
$ -371.55M
|
$ 239.02M
|
$ -395.11M
|
|
PE Ratio
|
38.53
|
|
|
|
|
|
